Cytek Biosciences (NASDAQ:CTKB) Trading Down 8.6% - Time to Sell?

Key Points

• Cytek Biosciences shares fell 8.6% to approximately $4.40, with trading volume down 81% from its average.
• Analyst sentiment is mixed: the stock has a consensus “Hold” rating and a $5.56 average price target, despite Buy ratings from three analysts and a Sell rating from one.
• The company reported quarterly revenue of $48.14 million, above estimates, but remains unprofitable with a negative net margin of 38.98% and analysts forecasting a full-year loss of $0.30 per share.

Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) fell 8.6% on Monday . The company traded as low as $4.45 and last traded at $4.3950. 189,283 shares traded hands during trading, a decline of 81% from the average daily volume of 1,014,185 shares. The stock had previously closed at $4.81.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on CTKB shares. Morgan Stanley set a $5.00 price objective on shares of Cytek Biosciences in a research report on Friday, August 7th. Stephens dropped their target price on shares of Cytek Biosciences from $5.50 to $4.75 and set an "overweight" rating on the stock in a research report on Wednesday, May 13th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Cytek Biosciences in a research note on Wednesday, June 24th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $5.56.

Cytek Biosciences Price Performance

The business has a fifty day moving average price of $4.44 and a two-hundred day moving average price of $4.37. The firm has a market capitalization of $568.66 million, a price-to-earnings ratio of -7.06 and a beta of 1.17.

Cytek Biosciences (NASDAQ:CTKB - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.09) EPS for the quarter, hitting analysts' consensus estimates of ($0.09). Cytek Biosciences had a negative return on equity of 12.40% and a negative net margin of 38.98%.The firm had revenue of $48.14 million during the quarter, compared to the consensus estimate of $47.31 million. On average, research analysts predict that Cytek Biosciences, Inc. will post -0.3 earnings per share for the current year.

Institutional Trading of Cytek Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of CTKB. Caitong International Asset Management Co. Ltd grew its stake in Cytek Biosciences by 86.6% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,144 shares of the company's stock valued at $26,000 after acquiring an additional 2,388 shares during the period. SBI Securities Co. Ltd. increased its holdings in Cytek Biosciences by 99.6% in the 4th quarter. SBI Securities Co. Ltd. now owns 5,010 shares of the company's stock worth $25,000 after acquiring an additional 2,500 shares in the last quarter. Intech Investment Management LLC raised its position in Cytek Biosciences by 6.7% during the fourth quarter. Intech Investment Management LLC now owns 51,740 shares of the company's stock worth $261,000 after acquiring an additional 3,242 shares during the period. Deutsche Bank AG raised its position in Cytek Biosciences by 4.6% during the fourth quarter. Deutsche Bank AG now owns 93,139 shares of the company's stock worth $470,000 after acquiring an additional 4,119 shares during the period. Finally, Federated Hermes Inc. lifted its holdings in Cytek Biosciences by 150.9% during the second quarter. Federated Hermes Inc. now owns 7,221 shares of the company's stock valued at $25,000 after purchasing an additional 4,343 shares in the last quarter. 69.46% of the stock is currently owned by institutional investors and hedge funds.

About Cytek Biosciences

Cytek Biosciences is a biotechnology company specializing in innovative cell analysis solutions. The firm develops and commercializes advanced spectral flow cytometry instruments and associated reagents designed to enable high-parameter single-cell analysis. Its technology platform offers researchers and clinicians enhanced sensitivity, resolution and flexibility compared to traditional flow cytometry methods.

The company's core product portfolio includes the Aurora and Northern Lights spectral cytometry systems, which support simultaneous detection of up to 64 fluorescence parameters.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source